ArticleDiscover oncology2025
Disulfidptosis OXSM serves as a potential prognostic biomarker and correlates with immune infiltrates in glioma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Experimental Detection Methods and Clinical Translational Challenges of Disulfidptosis in Cancer.Cells · 2026Review
- AMPK Suppresses Multiple Forms of Cell Death Including Disulfidptosis in Tumor-Associated Macrophages During Tumor Progression.International journal of molecular sciences · 2026Article
- Review
- RPN1 at the crossroads of glycosylation, tumor immunity, and disulfidptosis.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundGlioma, a common primary brain tumor arising from glial cells, presents significant therapeutic challenges due to its diverse and complex biological behavior. While disulfidptosis has recently emerged as a novel form of cell death, the role of disulfidptosis-related genes (DRGs) in glioma and their relationship with the tumor immune microenvironment remains poorly understood.
methodsWe analyzed DRGs expression patterns in glioma samples and their correlation with patient survival using data from TCGA, GEO, and CGGA databases. We employed ROC curve analysis to evaluate the diagnostic potential of individual DRGs and identify hub genes. We investigated the relationship between hub gene expression and immune cell infiltration through immune infiltration analysis. Additionally, we conducted drug sensitivity analysis and molecular docking to explore associations between hub gene expression and drug responsiveness. Finally, we validated DRGs expression in glioma samples using RT-PCR and tissue microarrays.
resultsAmong the ten DRGs examined, six genes (OXSM, SLC3A2, RPN1, NDUFS1, GYS1, and LRPPRC) showed significant differential expression in glioma tissues, while four (NCKAP1, NDUFA11, NUBPL, and SLC7A11) did not. Survival analysis revealed that elevated expression of OXSM, RPN1, GYS1, SLC3A2, and NDUFA11 correlated with poor patient outcomes. ROC analysis of both TCGA test and GEO validation sets identified OXSM as a hub gene, with AUC values exceeding 0.88. CGGA database analysis demonstrated higher OXSM expression in GBM compared to LGG, with peak expression in WHO grade IV tumors, significantly correlating with reduced overall survival (p < 0.01). Immune infiltration analysis showed that OXSM expression correlated with various immune cell populations, particularly significantly positively correlated with macrophages M0, M2, and T cells gamma delta, and significantly negatively correlated with monocytes. Drug sensitivity analysis indicated that high OXSM expression enhanced sensitivity to several therapeutic agents. RT-PCR and tissue microarray analyses confirmed elevated OXSM expression in high-grade gliomas.
conclusionOur study identifies OXSM as a key DRG hub gene in glioma, with elevated expression strongly correlating with poor patient prognosis. The observed relationship between OXSM expression and immune cell infiltration suggests its potential role in modulating the glioma microenvironment. These findings advance our understanding of glioma's molecular mechanisms and may inform the development of novel therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.